Systematic review: Current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 12, 2016, Pages 1276-1292

  Majumdar, A ^a,b   Kitson, M T ^a   Roberts, S K ^a  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; GS 9857; LEDIPASVIR; MULTIDRUG RESISTANCE PROTEIN; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VELPATASVIR; INTERFERON;

BRADYCARDIA; CITATION ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PORTAL HYPERTENSION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEROPREVALENCE; SYSTEMATIC REVIEW; TREATMENT FAILURE; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS;

EID: 84963894597     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13633     Document Type: Review

References (124)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
2. Hajarizadeh B, Grebely J, Dore GJ,. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-62.
3. Kim WR, Stock PG, Smith JM, et al,. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant 2013; 13 (Suppl. 1): 73-102.
4. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H,. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61 (1S): S45-57.
5. Denniston MM, Jiles RB, Drobeniuc J, et al,. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293-300.
6. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD,. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8.
7. Razavi H, Elkhoury AC, Elbasha E, et al,. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-70.
8. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21, 21 e1-6.
9. Thein HH, Yi Q, Dore GJ, Krahn MD,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
10. Bruix J, Sherman M,; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
11. Westbrook RH, Dusheiko G,. Natural history of hepatitis C. J Hepatol 2014; 61 (1S): S58-68.
12. Shiratori Y, Imazeki F, Moriyama M, et al,. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
13. Poynard T, McHutchison J, Manns M, et al,. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
14. Fontana RJ, Sanyal AJ, Ghany MG, et al,. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010; 138: 2321-31, 31 e1-2.
15. Roberts S, Gordon A, McLean C, et al,. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 932-7.
16. Shiratori Y, Ito Y, Yokosuka O, et al,. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-14.
17. Veldt BJ, Heathcote EJ, Wedemeyer H, et al,. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
18. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA,. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16 e1.
19. Bruno S, Stroffolini T, Colombo M, et al,. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
20. John-Baptiste AA, Tomlinson G, Hsu PC, et al,. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104: 2439-48.
21. van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
22. van der Meer AJ, Wedemeyer H, Feld JJ, et al,. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 2014; 312: 1927-8.
23. Bruno S, Shiffman ML, Roberts SK, et al,. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-97.
24. Valla DC, Chevallier M, Marcellin P, et al,. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-5.
25. Gramenzi A, Andreone P, Fiorino S, et al,. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001; 48: 843-8.
26. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR,. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplant 2002; 8: 350-5.
27. Everson GT, Trotter J, Forman L, et al,. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.
28. Iacobellis A, Siciliano M, Perri F, et al,. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-12.
29. Hezode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-41.
30. Scheel TK, Rice CM,. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-49.
31. Liang TJ, Ghany MG,. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907-17.
32. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML,. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci USA 2011; 108: 5777-82.
33. Wolk B, Sansonno D, Krausslich HG, et al,. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 2000; 74: 2293-304.
34. Clark VC, Peter JA, Nelson DR,. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013; 33 (Suppl. 1): 80-4.
35. Bartenschlager R, Lohmann V, Penin F,. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11: 482-96.
36. Masaki T, Suzuki R, Murakami K, et al,. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 2008; 82: 7964-76.
37. Tellinghuisen TL, Foss KL, Treadaway J,. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4: e1000032.
38. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM,. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol 2008; 82: 1073-83.
39. Appel N, Zayas M, Miller S, et al,. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 2008; 4: e1000035.
40. Berger C, Romero-Brey I, Radujkovic D, et al,. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Gastroenterology 2014; 147: 1094-105 e25.
41. Belda O, Targett-Adams P,. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res 2012; 170: 1-14.
42. Vermehren J, Sarrazin C,. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503.
43. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM,. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (Suppl. 1): S88-100.
44. Powdrill MH, Bernatchez JA, Gotte M,. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses 2010; 2: 2169-95.
45. Powdrill MH, Deval J, Narjes F, De Francesco R, Gotte M,. Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines. Antimicrob Agents Chemother 2010; 54: 977-83.
46. Rupp D, Bartenschlager R,. Targets for antiviral therapy of hepatitis C. Semin Liver Dis 2014; 34: 9-21.
47. Welzel TM, Dultz G, Zeuzem S,. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. J Hepatol 2014; 61 (1S): S98-107.
48. Kumar S, Jacobson IM,. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. J Hepatol 2014; 61 (1S): S91-7.
49. Martinot-Peignoux M, Stern C, Maylin S, et al,. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
50. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
51. Swain MG, Lai MY, Shiffman ML, et al,. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.
52. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
53. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
54. Liapakis A, Jacobson I,. Telaprevir user's guide. Clin Liver Dis 2011; 15: 555-71.
55. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
56. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
57. Muir AJ, Poordad FF, McHutchison JG, et al,. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011; 54: 1538-46.
58. Jacobson IM, Dore GJ, Foster GR, et al,. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
59. Manns M, Marcellin P, Poordad F, et al,. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26.
60. Forns X, Lawitz E, Zeuzem S, et al,. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79 e3.
61. Zeuzem S, Berg T, Gane E, et al,. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41 e6.
62. Reddy KR, Zeuzem S, Zoulim F, et al,. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 2015; 15: 27-35.
63. Manns MP, Fried MW, Zeuzem S, et al,. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. J Viral Hepat 2015; 22: 366-75.
64. Lawitz E, Sulkowski MS, Ghalib R, et al,. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.
65. Lawitz E, Matusow G, Dejesus E, et al,. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. J Hepatol 2015; 62 (Suppl. 2): S264.
66. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
67. Lawitz E, Poordad F, Brainard DM, et al,. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015; 61: 769-75.
68. Flamm SL, Bacon BR, Dietrich D, et al,. Evaluation of efficacy of sofosbuvir and simeprevir-based regimens in a real-life population of 345 HCV patients with cirrhosis; data from the TRIO network. Hepatology 2014; 60: 134A.
69. Foster GR, Pianko S, Brown A, et al,. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015; 149: 1462-70.
70. Hezode C, Hirschfield GM, Ghesquiere W, et al,. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015; 64: 948-56.
71. Jensen D, Sherman K, Hezode C, et al,. Daclatasvir and asunaprevir plus peginterferon alfa-2a and ribavirin in patients with HCV genotype 1 or 4 infection: Phase 3 HALLMARK-QUAD results. Open Forum Infect Dis 2014; Fall; 1 (Suppl. 1): S234.
72. Gambato M, Lens S, Navasa M, Forns X,. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol 2014; 61 (1S): S120-31.
73. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
74. Afdhal N, Reddy KR, Nelson DR, et al,. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
75. Gane E, Stedman C, Hyland RH, Pang P, Ding X, Symonds W,. All-oral sofosbuvir-based 12-weel regimens for the treatment of chronic HCV infection: the ELECTRON study. J Hepatol 2013; 58 (Suppl. 1): S6-7.
76. Bourliere M, Bronowicki JP, de Ledinghen V, et al,. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology 2014; 60 (Suppl. 1): 1270-1A.
77. Bourliere M, Sulkowski M, Omata M, et al,. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology 2014; 60 (Suppl. 1): 239A.
78. Wyles D, Pockros P, Yang C, et al,. Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. Hepatology 2014; 60 (Suppl. 1): 317A-8A.
79. Lawitz E, Flamm S, Yang JC, et al,. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol 2015; 62 (Suppl. 2): S192.
80. Poordad F, Hezode C, Trinh R, et al,. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.
81. Poordad F, Feld JJ, Trinh R, et al,. Turquoise-III: 12-week ribavirin-free regimen of ombitasvir/paritaprevir/r and dasabuvir for patients with HCV genotype 1B and cirrhosis. Hepatology 2015; 62 (Suppl. 1): 724A.
82. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie, 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm468634 (accessed 8 February 2016).
83. Chayama K, Suzuki F, Ikeda K, et al,. Ombitasvir/paritaprevir/ritonavir for treatment of HCV genotype 1b in Japanese patients with or without cirrhosis: results from GIFT-I. J Hepatol 2015; 62 (Suppl. 2): S235.
84. Reddy R, Lim JK, Kuo A, et al,. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: report from HCV-TARGET. J Hepatol 2015; 62 (Suppl. 2): S193.
85. Sarrazin C, Lathouwers E, Peeters M, et al,. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 2015; 116: 10-6.
86. Pearlman BL, Ehleben C, Perrys M,. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology 2015; 148: 762-70 e2; quiz e11-2.
87. Manns M, Pol S, Jacobson IM, et al,. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-605.
88. Suzuki F, Toyota J, Ikeda K, et al,. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther 2014; 19: 491-9.
89. Kumada H, Suzuki Y, Ikeda K, et al,. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-91.
90. Lawitz E, Gane E, Pearlman B, et al,. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385: 1075-86.
91. Zeuzem S, Ghalib R, Reddy KR, et al,. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163: 1-13.
92. Kwo P, Gane E, Peng C-Y, et al,. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks with HCV G1 or G4 infection who previously failed Peginterferon/RBV: C-EDGE treatment-experienced trial. J Hepatol 2015; 62 (Suppl. 1): S674-5.
93. Buti M, Gordon SC, Zuckerman E, et al,. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis c virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis 2016; 62: 32-6.
94. Forns X, Gordon SC, Zuckerman E, et al,. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015; 63: 564-72.
95. Jacobson I, Lawitz E, Kwo P, et al,. An integrated analysis of 402 compensated cirrhotic patients with HCV genotype (GT) 1, 4 or 6 infection treated with grazoprevir/elbasvir. Hepatology 2015; 62 (Suppl. 1): 229A.
96. Food and Drug Administration. FDA News Release: FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4, 2016. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm (accessed 8 February 2016).
97. Poordad E, Lawitz E, Gutierrez JA, et al,. C-SWIFT: grazoprevir/Elbasvir + sofosbuvir in cirrhotic and non-cirrhotic, treatment-naive patients with hepatitis C virus genoptype 1 infection for durations of 4, 6, or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. J Hepatol 2015; 62 (Suppl. 2): S192-3.
98. Pianko S, Flamm SL, Shiffman ML, et al,. High efficacy of treatment with sofosbuvir+GS-5816 ± ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection. Hepatology 2014; 60 (Suppl. 1): 297-8A.
99. Feld JJ, Jacobson IM, Hezode C, et al,. Sofosbuvir and velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373: 2599-607.
100. Gane EJ, Hyland RH, Ying Y, et al,. Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naïve and DAA-experienced geno- type 1 patients with and without cirrhosis. J Hepatol 2015; 2015: S264.
101. Lalezari JP, Nelson DR, Hyland RH, et al,. Once-daily sofosbuvir plus ribavirin given for 12 or 24 weeks in treatment-naive patients with HCV: the QUANTUM study. J Hepatol 2013; 58: S346.
102. Osinusi A, Meissner EG, Lee YJ, et al,. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-11.
103. Ruane PJ, Ain D, Stryker R, et al,. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62: 1040-6.
104. Doss W, Shiha G, Hassany M, et al,. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015; 63: 581-5.
105. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
106. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
107. Foster GR, Afdhal N, Roberts SK, et al,. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373: 2608-17.
108. Nelson DR, Cooper JN, Lalezari JP, et al,. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology 2015; 61: 1127-35.
109. Leroy V, Angus PW, Bronowicki JP, et al,. All-oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3 + phase 3 study. Hepatology 2015; 62 (Suppl. 1): 1380A-1A.
110. Hezode C, de Ledinghen V, Fontaine H, et al,. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology 2015; 62 (Suppl. 1): 314A.
111. Everson GT, Tran TT, Towner WJ, et al,. Safety and efficacy of treatment with the interferon-free ribavirin-free combination of sofosbuvir + GS5816 for 12 weeks in treatment naive patients with genotype 1-6 HCV infection. J Hepatol 2014; 60 (Suppl. 1): S46.
112. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
113. Poordad E, Schiff ER, Vierling JM, et al,. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. J Hepatol 2015; 62 (Suppl. 2): S261.
114. Curry MP, Forns X, Chung RT, et al,. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-7 e1.
115. Charlton M, Everson GT, Flamm SL, et al,. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-59.
116. Manns M, Forns X, Samuel D, et al,. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post-liver transplant patients with HCV infection: preliminary results of the SOLAR-2 trial. J Hepatol 2015; 62 (Suppl. 2): S187.
117. Foster GR, McLauchlan J, Irving W, et al,. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol 2015; 62 (Suppl. 2): S190.
118. Curry MP, O'Leary JG, Bzowej N, et al,. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618-28.
119. Mantry PS, Kwo PY, Coakley E, Te HS, Vargas HE, Brown RS Jr,. High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection receiving ABT-450/r/ombitasvir+dasabuvir plus ribavirin. Hepatology 2014; 60 (Suppl. 1): S298A-9A.
120. Coilly A, Fougerou C, de Ledinghen V, et al,. The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: results from a large French prospective multicentric ANRS CO23 CUPILT Cohort. J Hepatol 2015; 62 (Suppl. 2): S236.
121. Welzel TM, Herzer K, Ferenci P, Petersen J, Gschwantler M, Cornberg M,. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicentre compassionate use program. J Hepatol 2015; 62 (Suppl. 2): S619-20.
122. Kwo P, Mantry P, Coakley E, Te HS, Vargas HE, Brown RS Jr,. Results of the phase 2 study of ABT-450/r/ABT-267 + ABT-333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. J Hepatol 2014; 60 (Suppl. 1): S47.
123. Food and Drug Administration. FDA hepatitis update-important safety information: Harvoni and Sovaldi, 2015. Available at: http://content.govdelivery.com/accounts/USFDA/bulletins/f97c71 (accessed 2 July 2015).
124. Zeuzem S, Mizokami M, Pianko S, et al,. Prevalence of pre-treatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV/SOF. Hepatology 2015; 62 (Suppl. 1): 254A-5A.